Post-mortem analýza průlomové infekce Candida albicans při léčbě echinokandiny u pacienta po transplantaci kmenových buněk krvetvorby

English version

Autoři: V. Chrenkova ¹; P. Hubacek ^1,2; P. Sedlacek ²; P. Riha ²; D. Kodetová ³; E. Bébrová ⁴
Působiště autorů: Department of Medical Microbiology nd Faculty of Medicine, Charles University in Prague and Motol University Hospital ¹; Department of Paediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital ²; Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital ³; Department of Medical Microbiology, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital ⁴
Vyšlo v časopise: Epidemiol. Mikrobiol. Imunol. 63, 2014, č. 2, s. 121-124
Kategorie: Souhrnná sdělení, původní práce, kazuistiky

Souhrn

Představujeme případ úmrtí dívky na průlomovou infekci Candida albicans při léčbě echinokandiny po transplantaci kmenových buněk krvetvorby pro relaps akutní myeloidní leukémie. Hemokultivace prokázaly opožděně přítomnost rezistence na echinokandiny u kmene Candida albicans, která je obvykle považována za dobře citlivou k antimykotické terapii. Echinokandin podávaný v profylaxi nebyl z důvodu závažných orgánových komplikací (játra, ledviny) změněn na preparát z jiné skupiny ani v léčbě invazivní infekce. Později provedené molekulární analýzy prokázaly přítomnost mutace S645P, popsané jako příčiny rezistence k echinokandinům. Dále byla provedena post-mortem analýza nálože kvasinkové infekce ve tkáních, která prokázala velmi vysoké kvantity kvasinkové DNA v zažívacím traktu, játrech, slezině a ledvinách.

Klíčová slova:
invazivní kandidová onemocnění – transplantace kmenových buněk krvetvorby – rezistence na echinokandiny

Zdroje

1. Arendrup MC, et al. Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrob Agents Chemother, 2009;53(3):1185–1193.

2. Ascioglu S, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis, 2002;34(1):7–14.

3. Benjamin DK Jr. et al. Infections diagnosed in the first year after pediatric stem cell transplantation. Pediatr Infect Dis J, 2002;21(3):227–234.

4. Campana D, Leung W. Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation. Br J Haematol, 2013;162(2):147–161.

5. Canton E, Espinel-Ingroff A, Peman, J. Trends in antifungal susceptibility testing using CLSI reference and commercial methods. Expert Rev Anti Infect Ther, 2009;7(1): 107–119.

6. Castanheira M, et al. Low Prevalence of fks1 Hotspot 1 Mutations in a Worldwide Collection of Candida spp. Antimicrob Agents Chemother, 2010;54(6):2655–2659.

7. Douglas CM, et al. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother, 1997;41(11):2471–2479.

8. Garcia-Effron G, Park S, Perlin DS. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother, 2009;53(1):112–122.

9. Hale KA, et al. Epidemiology of paediatric invasive fungal infections and a case-control study of risk factors in acute leukaemia or post stem cell transplant. Br J Haematol, 2010;149(2):263–272.

10. Herbrecht R, et al. Indications and outcomes of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic stem cell transplantation. J Antimicrob Chemother, 2012;67(11):2731–2738.

11. Hernandez S, et al. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother, 2004;48(4):1382–1383.

12. Hope WW, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect, 2012;18(Suppl 7):38–52.

13. Horn DL, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis, 2009;48(12):1695–1703.

14. Katiyar S, Pfaller M, Edlind T. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob Agents Chemother, 2006;50(8): 2892–2894.

15. Khlif M, et al. Evaluation of nested and real-time PCR assays in the diagnosis of candidaemia. Clin Microbiol Infect, 2009;15(7):656–661.

16. Kocmanova I, et al. Invasive candidiasis in selected heamatology departments in the Czech Republic and Slovakia – microbiological results of the CAN CELL project. Klin Mikrobiol Infekc Lek, 2011;17(1):5–10.

17. Laverdiere M, et al. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother, 2006;57(4):705–708.

18. Maertens J, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 Update. Bone Marrow Transplant, 2011;46(5):709–1718.

19. Mor M, et al. Invasive fungal infections in pediatric oncology. Pediatr Blood Cancer, 2011;56(7):1092–1097.

20. Niimi K, et al. Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSC1 (FKS1) allele followed by loss of heterozygosity. J Antimicrob Chemother, 2010;65(5):842–852.

21. Park S, et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother, 2005;49(8):3264–3273.

22. Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat, 2007;10(3):121–130.

23. Pfeiffer CD, et al. Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol, 2010;48(7):2373–2380.

24. Pongers-Willemse MJ, et al. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia, 1998;12(12):2006–2014.

25. Slater JL, et al. Disseminated candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin. Antimicrob Agents Chemother, 2011;55(7):3075–3083.

26. Steinbach WJ, et al. Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates. Pediatr Infect Dis J, 2012;31(12):1252–1257.

27. Vella A, et al. Rapid antifungal susceptibility testing by matrix-assisted laser desorption ionization-time of flight mass spectrometry analysis. J Clin Microbiol, 2013;51(9):2964–2969.

28. White PL, Archer AE, Barnes RA. Comparison of non-culture-based methods for detection of systemic fungal infections, with an emphasis on invasive Candida infections. J Clin Microbiol, 2005;43(5):2181–2187.